FINWIRES · TerminalLIVE
FINWIRES

UBS Downgrades Legend Biotech to Neutral From Buy, Adjusts Price Target to $28 From $49

By

Legend Biotech (LEGN) has an average rating of overweight and mean price target of $53.73, according to analysts polled by FactSet.

What else is happening in Research?